Search

Your search keyword '"Miekoutima, Elsa"' showing total 11 results
Start Over Author "Miekoutima, Elsa"
11 results on '"Miekoutima, Elsa"'

1. Subcutaneous azacitidine maintenance in transplantineligible patients with acute myeloid leukemia: a single-center retrospective study

Author

Johnson, Natacha, primary, Templé, Marie, additional, Friedrich, Chloe, additional, Willems, Lise, additional, Birsen, Rudy, additional, Vignon, Marguerite, additional, Deschamps, Paul, additional, Franchi, Patricia, additional, Mondesir, Johanna, additional, Deau-Fischer, Benedicte, additional, Miekoutima, Elsa, additional, Boussaid, Ismaël, additional, Chapuis, Nicolas, additional, Kosmider, Olivier, additional, Bouscary, Didier, additional, Tamburini, Jerome, additional, and Decroocq, Justine, additional

Published
2023
Full Text
View/download PDF

2. Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron Era

Author

Zerbit, Jeremie, primary, Detroit, Marion, additional, Meyer, Antoine, additional, Decroocq, Justine, additional, Deau-Fischer, Benedicte, additional, Deschamps, Paul, additional, Birsen, Rudy, additional, Mondesir, Johanna, additional, Franchi, Patricia, additional, Miekoutima, Elsa, additional, Guerin, Corinne, additional, Batista, Rui, additional, Bouscary, Didier, additional, Willems, Lise, additional, and Vignon, Marguerite, additional

Published
2022
Full Text
View/download PDF

4. Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)

Author

Cluzeau, Thomas, primary, Sebert, Marie, additional, Rahmé, Ramy, additional, Cuzzubbo, Stefania, additional, Lehmann-Che, Jacqueline, additional, Madelaine, Isabelle, additional, Peterlin, Pierre, additional, Bève, Blandine, additional, Attalah, Habiba, additional, Chermat, Fatiha, additional, Miekoutima, Elsa, additional, Rauzy, Odile Beyne, additional, Recher, Christian, additional, Stamatoullas, Aspasia, additional, Willems, Lise, additional, Raffoux, Emmanuel, additional, Berthon, Céline, additional, Quesnel, Bruno, additional, Loschi, Michael, additional, Carpentier, Antoine F., additional, Sallman, David A., additional, Komrokji, Rami, additional, Walter-Petrich, Anouk, additional, Chevret, Sylvie, additional, Ades, Lionel, additional, and Fenaux, Pierre, additional

Published
2021
Full Text
View/download PDF

5. APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)

Author

Cluzeau, Thomas, primary, Sebert, Marie, primary, Rahmé, Ramy, primary, Cuzzubbo, Stefania, primary, Walter-petrich, Anouk, primary, Lehmann che, Jacqueline, primary, Peterlin, Pierre, primary, Beve, Blandine, primary, Attalah, Habiba, primary, Chermat, Fatiha, primary, Miekoutima, Elsa, primary, Beyne-Rauzy, Odile, primary, Recher, Christian, primary, Stamatoullas, Aspasia, primary, Willems, Lise, primary, Raffoux, Emmanuel, primary, Berthon, Céline, primary, Quesnel, Bruno, primary, Carpentier, Antoine, primary, Sallman, David A, primary, Chevret, Sylvie, primary, Ades, Lionel, primary, and Fenaux, Pierre, primary

Published
2019
Full Text
View/download PDF

6. Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia

Author

Maslah, Nabih, primary, Salomao, Norman, additional, Drevon, Louis, additional, Verger, Emmanuelle, additional, Partouche, Nicolas, additional, Ly, Pierre, additional, Aubin, Philippe, additional, Naoui, Nadia, additional, Schlageter, Marie-Helene, additional, Bally, Cecile, additional, Miekoutima, Elsa, additional, Rahmé, Ramy, additional, Lehmann-Che, Jacqueline, additional, Ades, Lionel, additional, Fenaux, Pierre, additional, Cassinat, Bruno, additional, and Giraudier, Stephane, additional

Published
2019
Full Text
View/download PDF

8. Respective roles of migration and social deprivation for virological non-suppression in HIV-infected adults on antiretroviral therapy in France

Author

Raho-Moussa, Mariem, primary, Guiguet, Marguerite, additional, Michaud, Céline, additional, Honoré, Patricia, additional, Palacios, Christia, additional, Boué, François, additional, Azghay, Mohammed, additional, Kansau, Imad, additional, Chambrin, Véronique, additional, Kandel, Tania, additional, Favier, Marion, additional, Miekoutima, Elsa, additional, Sayre, Naomi, additional, Pignon, Carole, additional, Shoai, Michka, additional, Bouchaud, Olivier, additional, and Abgrall, Sophie, additional

Published
2019
Full Text
View/download PDF

9. Eprenetapopt Plus Azacitidine in -Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM).

Author

Cluzeau, Thomas, Sebert, Marie, Rahmé, Ramy, Cuzzubbo, Stefania, Lehmann-Che, Jacqueline, Madelaine, Isabelle, Peterlin, Pierre, Bève, Blandine, Attalah, Habiba, Chermat, Fatiha, Miekoutima, Elsa, Rauzy, Odile Beyne, Recher, Christian, Stamatoullas, Aspasia, Willems, Lise, Raffoux, Emmanuel, Berthon, Céline, Quesnel, Bruno, Loschi, Michael, and Carpentier, Antoine F

Published
2021
Full Text
View/download PDF

10. APR-246 Combined with Azacitidine (AZA) in TP53Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)

Author

Cluzeau, Thomas, Sebert, Marie, Rahmé, Ramy, Cuzzubbo, Stefania, Walter-petrich, Anouk, Lehmann che, Jacqueline, Peterlin, Pierre, Beve, Blandine, Attalah, Habiba, Chermat, Fatiha, Miekoutima, Elsa, Beyne-Rauzy, Odile, Recher, Christian, Stamatoullas, Aspasia, Willems, Lise, Raffoux, Emmanuel, Berthon, Céline, Quesnel, Bruno, Carpentier, Antoine, Sallman, David A, Chevret, Sylvie, Ades, Lionel, and Fenaux, Pierre

Abstract

Introduction: TP53mutated (TP53m) MDS and AML have very poor outcome irrespective of the treatment received, including 40% responses (20% CR) with azacitidine (AZA) with short response duration and a median overall survival (OS) of about 8 months (Bejar, Blood 2014). APR-246 is a prodrug spontaneously converted to methylene quinuclidinone (MQ), a Michael acceptor that binds covalently to cysteines in mutant p53, leading to protein reconformation that reactivates its pro apoptotic and cell cycle arrest functions. The combination of AZA and APR 246 showed promising results in a phase Ib study in TP53mMDS (Sallman, ASH 2018). We report interim results of a GFM phase 2 study of AZA+ APR-246 in TP53mMDS and AML, conducted in parallel with a similar US MDS consortium study.

Published
2019
Full Text
View/download PDF

11. Synergistic effects of PRIMA-1 Met (APR-246) and 5-azacitidine in TP53 -mutated myelodysplastic syndromes and acute myeloid leukemia.

Author

Maslah N, Salomao N, Drevon L, Verger E, Partouche N, Ly P, Aubin P, Naoui N, Schlageter MH, Bally C, Miekoutima E, Rahmé R, Lehmann-Che J, Ades L, Fenaux P, Cassinat B, and Giraudier S

Subjects
Aza Compounds, Azacitidine pharmacology, Bridged Bicyclo Compounds, Heterocyclic, Humans, Quinuclidines, Tumor Suppressor Protein p53 genetics, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute genetics, Myelodysplastic Syndromes drug therapy, Myelodysplastic Syndromes genetics
Abstract

Myelodysplastic syndromes and acute myeloid leukemia with TP53 mutations are characterized by frequent relapses, poor or short responses, and poor survival with the currently available therapies including chemotherapy and 5-azacitidine (AZA). PRIMA-1 Met (APR-246,APR) is a methylated derivative of PRIMA-1, which induces apoptosis in human tumor cells through restoration of the transcriptional transactivation function of mutant p53. Here we show that low doses of APR on its own or in combination with AZA reactivate the p53 pathway and induce an apoptosis program. Functionally, we demonstrate that APR exerts these activities on its own and that it synergizes with AZA in TP53 -mutated myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML) cell lines and in TP53 -mutated primary cells from MDS/AML patients. Low doses of APR on its own or in combination with AZA also show significant efficacy in vivo Lastly, using transcriptomic analysis, we found that the APR + AZA synergy was mediated by downregulation of the FLT3 pathway in drug-treated cells. Activation of the FLT3 pathway by FLT3 ligand reversed the inhibition of cell proliferation by APR + AZA. These data suggest that TP53 -mutated MDS/AML may be better targeted by the addition of APR-246 to conventional treatments., (Copyright© 2020 Ferrata Storti Foundation.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results